Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study

World Journal of Urology

Volumn 32, Issue 4, 2014, Pages 1049-1054

  Yassin, Dany Jan ^a   El Douaihy, Yousef ^b   Yassin, Aksam A ^b,c   Kashanian, James ^d   Shabsigh, Ridwan ^d   Hammerer, Peter G ^a  

^a KLINIKUM BRAUNSCHWEIG   (Germany)

^b Institute of Urology and Andrology at Segeberger Kliniken   (Germany)

^c DRESDEN INTERNATIONAL UNIVERSITY   (Germany)

^d MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

BPH; IPSS; LOH; LUTS; Testosterone

Indexed keywords

IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SULFONE; TESTOSTERONE; TRIAZINE DERIVATIVE; VARDENAFIL;

AGED; COMPLICATION; ERECTILE DYSFUNCTION; EUNUCHOIDISM; HORMONE SUBSTITUTION; HUMAN; LONGITUDINAL STUDY; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; ONSET AGE; PROSPECTIVE STUDY; REGISTER; TREATMENT OUTCOME;

AGE OF ONSET; AGED; ERECTILE DYSFUNCTION; EUNUCHISM; HORMONE REPLACEMENT THERAPY; HUMANS; IMIDAZOLES; LONGITUDINAL STUDIES; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; REGISTRIES; SULFONES; TESTOSTERONE; TREATMENT OUTCOME; TRIAZINES;

EID: 84900011854     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1187-z     Document Type: Article

References (26)

1. Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R (2006) Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 38: 1-12.
2. Yassin AA, El-Sakka AI, Saad F, Gooren LJ (2008) Lower urinary-tract symptoms and testosterone in elderly men. World J Urol 26: 359-364.
3. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, Smit E, Giovannucci E, Platz EA (2007) Serum sex steroid hormones and lower urinary tract symptoms in third national health and nutrition examination survey (NHANES III). Urology 69: 708-713.
4. Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26: 833-876.
5. McVary KT, Rademaker A, Lloyd GL, Gann P (2005) Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 174: 1327-1433.
6. Shabsigh R (1997) The effects of testosterone on the cavernous tissue and erectile function. World J Urol 15: 21-26.
7. Rhoden EL, Riedner CE, Fornari A, Fuchs SC, Ribeiro EP (2008) Evaluation of the association between lower urinary tract symptoms and erectile dysfunction, considering its multiple risk factors. J Sex Med 5: 2662-2668.
8. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW (2002) Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168: 599-604.
9. Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G, Gassner C, Ochsner M, Marberger M (2003) Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 169: 1312-1315.
10. Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB (2007) An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int 100: 321-326.
11. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I (1999) Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 140: 1861-1868.
12. Stage AC, Hairston JC (2005) Symptom scores: mumbo jumbo or meaningful measures? Curr Urol Rep 6: 251-256.
13. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071-1077.
14. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401-1407.
15. Zhang X, Zang N, Wei Y, Yin J, Teng R, Seftel A, Disanto ME (2012) Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab 302: E243-E253.
16. Saboor Aftab SA, Kumar S, Barber TM (2013) The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocriol (Oxf) 78: 330-337.
17. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 12: 305-311.
18. Vermeulen A (2001) Androgen replacement therapy in the aging male-a critical evaluation. J Clin Endocrinol Metab 86: 2380-2390.
19. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM (1983) The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 57: 557-562.
20. Rosenzweig BA, Bolina PS, Birch L, Moran C, Marcovici I, Prins GS (1995) Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn 14: 87-96.
21. Celayir S (2003) Effects of different sex hormones on male rabbit urodynamics: an experimental study. Horm Res 60: 215-220.
22. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M (2007) Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148: 1019-1029.
23. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M (2011) Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 8: 2746-2760.
24. Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L (2013) The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 63: 506-516.
25. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L, Heufelder A, Jones H, Meryn S, Zitzmann M (2008) The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract 62: 791-798.
26. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT (2006) Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2: 146-159.